Acadian Asset Management
SNDX icon

Acadian Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Acadian Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,892
Closed -$67K – 2220
2026
Q1 		$67K Sell
2,892
-7,277
-72% -$158K ﹤0.01% 1818
2025
Q4 		$213K Buy
10,169
+8,477
+501% +$148K ﹤0.01% 1512
2025
Q3 		$26K Buy
+1,692
New +$22.1K ﹤0.01% 1743
2024
Q4 		– Sell
-10,200
Closed -$196K – 2127
2024
Q3 		$196K Buy
+10,200
New +$211K ﹤0.01% 1373
2020
Q2 		– Sell
-12,301
Closed -$135K – 2331
2020
Q1 		$135K Buy
12,301
+2,440
+25% +$22.9K ﹤0.01% 1288
2019
Q4 		$87K Sell
9,861
-19,203
-66% -$141K ﹤0.01% 1506
2019
Q3 		$217K Buy
29,064
+8,559
+42% +$78K ﹤0.01% 1302
2019
Q2 		$191K Buy
+20,505
New +$149K ﹤0.01% 1236
2018
Q3 		– Sell
-2,963
Closed -$21K – 1782
2018
Q2 		$21K Buy
+2,963
New +$29.1K ﹤0.01% 1524

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Acadian Asset Management's SNDX Position: Q2 2026 in Review

Acadian Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 2,892 shares — an estimated $67K sold.

Acadian Asset Management first reported a position in SNDX in Q2 2018 and held it in 9 quarters. The position peaked at $217K in Q3 2019. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Acadian Asset Management reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 2,892 Syndax Pharmaceuticals shares in Q2 2026, an estimated $67K.
  • Acadian Asset Management first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 9 quarters.
  • Acadian Asset Management's Syndax Pharmaceuticals position peaked at $217K in Q3 2019.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.